Myocardial reperfusion: Biology, benefits and consequences

Dialogues in Cardiovascular Medicine

Volumn 11, Issue 4, 2006, Pages 267-278

  Willerson, James T ^a   Buja, L Maximilian ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Mycrocardial hiberation; Myocardial stunning; Reperfusion; Reperfusion injury

Indexed keywords

5 HYDROXYDECANOIC ACID; ACETYLSALICYLIC ACID; ADENINE NUCLEOTIDE; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE TRIPHOSPHATASE (POTASSIUM); ANTIOXIDANT; CALCIUM; CALCIUM ANTAGONIST; CHELERYTHRINE; CLOPIDOGREL; DIAZOXIDE; FREE RADICAL; GLIBENCLAMIDE; GLYCOGEN; HEPARIN DERIVATIVE; LACTIC ACID; LOW MOLECULAR WEIGHT HEPARIN; NITRATE; PHOSPHATE; PROTON; TRIMETAZIDINE;

ACIDOSIS; ANGIOPLASTY; ARTICLE; BIOACCUMULATION; BLOOD CLOT LYSIS; BLOOD VESSEL INJURY; CELL PH; CORONARY ARTERY BYPASS SURGERY; DEPLETION; DISEASE SEVERITY; DRUG MECHANISM; EDEMA; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; INFLAMMATION; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; LIPID PEROXIDATION; MEMBRANE DAMAGE; MICROVASCULATURE; MITOCHONDRION; NONHUMAN; SALVAGE THERAPY; SARCOLEMMA; STUNNED HEART MUSCLE; THROMBOCYTE ACTIVATION; THROMBOSIS;

EID: 34249908638     PISSN: 12729949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: Part I. Circulation. 2001;104:2981-2989.
2. Kioner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: Part 2. Circulation. 2001;104:3158-367.
3. Reimer KA, Jennings RB. The "wavefront phenomenon" of myocardial ischemic cell death: II Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest. 1979;40;633-644.
4. Willerson JT, Scales F, Mukherjee A, et al. Abnormal myocardial fluid retention as an early manifestation of ischemic injury. Am J Pathol. 1977;87:159-188.
5. Willerson JT, Parkey RW, Bonte FJ, Lewis SE, Corbett J, Buja LM. Pathophysiologic considerations and clinocopathological correlates of technetium-99m stannous pyrophosphate myocardial scintigraphy. Sem Nucl Med. 1980;1O:54-69.
6. Jennings RB, Reimer KA, Hill ML, et al. Total ischemia in dog hearts, in vitro. 1. Comparison of high energy phosphate production, utilization, and depletion, and of adenine nucleotide catabolism in total ischemia in vitro versus severe ischemia in vivo. Circ Res. 1981;49:892-900.
7. Kostin S. Pathways of myocyte death: Implications for development of clinical laboratory biomarkers. Adv Clin Chem. 2005;40:37-98.
8. Kloner RA, Ganote CE, Jennings RB. The no reflow phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54:1496-1508.
9. Willerson JT, Watson JT, Hutton I, Templeton GH, Fixier DE. Reduced myocardial reflow and increased coronary vascular resistance following prolonged myocardial ischemia in the dog. Circ Res. 1975;36:771-781.
10. Buja LM. Modulation of the myocardial response to ischemia. Lab Invest. 1998;78:1345-1373.
11. Reimer K, Hill ML, Jennings RB. Prolonged depletion of ATP and of the adenine nucleotides pool due to delayed resynthesis of adenine nucleotides following reversible myocardial ischemic injury in dogs. J Mol Cell Cordiol. 1981;13:229-239.
12. Heyndrickx GR, Baig H, Nellens P, et al. Depression of regional blood flow and wall thickening after brief coronary occlusions. Am J Physiol. 1978;234:H653-H659.
13. Braunwald E, Kloner RA. The stunned myocardium: Prolonged, post-ischemic ventricular dysfunction. Circulation. 1982;66:1146-1 149.
14. Bush LR, Buja LM, Tilton G, et al. Effects of propranolol and diltiazem alone and in combination on the recovery of left ventricular segmental function after long-term repefusion following temporary coronary occlusion in conscious dogs. Circulation. 1985;72:413-430.
15. Bolli R, Zhu WX, Thornby JL, et al. Time-course and determinants of recovery of function after reversible ischemia in conscious dogs. Am J Physiol. 1988;254:H102-H114.
16. Bolli R, Jeroudi MO, Patel BS, et at. Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. Proc Natl Acad Sci U S A. 1989;86:4695-4699.
17. Bolli R, Patel BS, Jeroudi MO, et al. Demonstration of free radical generation in "stunned" myocardium of intact dogs with the use of the spin trap alpha-phenyl N-tertiary butyl nitrone. J Clin Invest. 1988;82:476-485.
18. McDonough JL, Arrell DK, VanEyk JE. Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury. Circ Res. 1999;84:9-20.
19. Gao WD, Atar D, Liu Y, et al. Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res. 1997;80:393-399.
20. Rahimtoola SH. The hibernating myocardium. Am Heart J. 1989;117:211-221.
21. Kloner RA, Bolli R, Marban E, et al. Medical and cellular implications of stunning, hibernation, and preconditioning: An NHLBI Workshop. Circulation. 1998;97:1848-1867.
22. Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall motion abnormalities predicted by positron emission tomography. N Engl J Med. 1986;314:884-888.
23. Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J Med. 1998;339:173-181.
24. Buja LM. Myocardial ischemia and reperfusion injury. Cardiovasc Pathol. 2005;14:170-175.
25. Jugdutt BI, Idikio HA. Apoptosis and oncosis in acute coronary syndromes: Assessment and implications. Mol Cell Biochem. 2005;270:177-200.
26. Garg S, Hofstra L, Reutelingsperger C, Narula J. Apoptosis as a therapeutic target in acutely ischemic myocardium. Curr Opin Cardiol. 2003;18:372-377.
27. Elsässer A, Vogt AM, Nef H, et al. Human hibernating myocardium is jeopardized by apoptotic and autophagic cell death. J Am Coll Cardiol. 2004;43:2191-2199.
28. Forman MB, Virmani R, Puett DW. Mechanisms and therapy of myocardial reperfusion injury. Circulation. 1990;81(suppl IV):IV69-IV78.
29. Hearse DJ, Bolli R. Reperfusion induced injury: Manifestations, mechanisms, and clinical relevance. Cardiovasc Res. 1992;26:101-108.
30. Moens AL, Claeys MJ, Timmermans JP, Vrints CJ. Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol. 2005;100:179-190.
31. Bolli R, Jeroudi MO, Patel BS, et al. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion: Evidence that myocardial "stunning" is a manifestation of reperfusion injury. Circ Res. 1989;65:607-622.
32. Myers ML, Bolli R. Lekich RF, et al. Enhancement of recovery of myocardial function by oxygen free-radical scavengers after reversible regional ischemia. Circulation. 1985;72:915-921.
33. Przyklenk K, Kloner RA. Superoxide dismutase plus catalase improve contractile function in the canine model of the "stunned myocardium". Circ Res. 1986;58:148-156.
34. Bolli R, Patel BS, Zhu WX, et al. The iron chelator desferrioxamine attenuated postischemic ventricular dysfunction. Am J. Physiol. 1987;253:H1372-H1380.
35. Farber NE, Vercellotti GM, Jacob HS, et al. Evidence for a role of iron-catalyzed oxidants in functional and metabolic stunning in canine heart. Circ Res. 1988; 63:351-360.
36. Iskesen I, Saribulbul O, Cerrahoglu M, Var A, Nazli Y, Sirin H. Trimetazidine reduces oxidative stress in cardiac surgery. Circ J. 2006;70:1169-1173.
37. Tunerir B, Coiak O, Alatas O, Besogul Y, Kural T, Asian R. Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann Thorac Surg. 1999;68:2173-2176.
38. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation. 1986;14:1124-1136.
39. Jennings RB, Sebbag L, Schwartz LM, et al. Metabolism of preconditioned myocardium: Effect of loss and reinstatement of cardioprotection. J Mol Cell Cardiol. 2001;33:1571-1588.
40. Cohen MV, Yang XM, Downey JM. Conscious rabbits become tolerant to multiple episodes of ischemic preconditioning. Circ Res. 1994;74:998-1004.
41. ATP channel opening during index ischemia and following myocardial reperfusion in ischemic rat hearts. J Mol Cell Cardiol. 2001;33:651-653.
42. Murry CE, Richard VJ, Reimer KA, et al. Ischemic preconditioning slows energy metabolism and delays ultra-structural damage during a sustained ischemic episode. Circ Res. 1990;66:913-931.
43. Yellon DM, Downey JM. Preconditioning the myocardium: From cellular physiology to clinical cardiology. Physiol Rev. 2003;83:1113-1151.
44. Weiss RG, de Albuquerque CP, Vandegaer K, et al. Attenuated glycogenolysis reduces glycolytic catabolite accumulation during ischemia in preconditioned rat hearts. Circ Res. 1996;79:435-446.
45. ATP channel opening is important during index ischemia and following myocardial reperfusion in ischemic preconditioned rat hearts. J Mol Cell Cordiol. 2001;33:831-834.
46. Okin PM, Mailk M, Hnatkova K, et al. Repolarization abnormality for prediction of all-cause and cardiovascular mortality in American Indians: The Strong Heart Study. J Cardiovasc Electrophysiol. 2005;16:945-951.
47. Ping P, Zhang J. Zheng YT, et al. Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits. Circ Res. 1999;85:542-550.
48. Vahlhaus C, Schulz R. Post H, et al. No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine Circ Res. 1996;79:407-414.
49. 3 adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms. Circ Res. 2001;88:520-528.
50. Yellon DM, Baxter GF. A second window of protection or delayed protection preconditioning phenomenon: Future horizons for myocardial protection? J Mol Cell Cardiol. 1995;27:1023-1034.
51. Virmani R, Burke AP, Farb A, Kotodgie FD. Pathology of the vulnerable plaque. Am Coll Cardiol. 2006;47(suppl C): C13-C18.
52. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation. 1989;80:198-205.
53. Hochman JS, Lamas Ga, Buller CE, et al; Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355:2475-2477.
54. Casthly PA, Shah C, Merhjian H, et al. Left ventricular diastolic function after coronary artery bypass grafting. A correlative study with three different myocardial protection techniques. J Thor Cardiovasc Surg. 1997;114:254-260.